期刊文献+

齐拉西酮联合碳酸锂治疗双相情感障碍躁狂发作的临床效果分析 被引量:12

下载PDF
导出
摘要 目的分析齐拉西酮联合碳酸锂治疗双相情感障碍躁狂发作的临床疗效和安全性。方法选取在广州市民政局精神病院就诊的双相情感障碍患者78例作为研究对象,按治疗方法的不同,分为对照组和观察组,各39例,对照组仅给予碳酸锂治疗,观察组在对照组基础上联合齐拉西酮治疗,治疗8周后采用Beck-Rafaelsen狂躁量表(BRMS)对两组患者的临床疗效进行评定,并记录两组患者的不良反应发生情况。结果观察组治疗后BRMS评分较对照组低,差异有统计学意义(P<0.05);观察组有效率为94.87%,对照组有效率为76.92%,差异有统计学意义(P<0.05);观察组不良反应发生率为15.38%,对照组不良反应发生率为10.26%,但差异无统计学意义(P>0.05)。结论碳酸锂联合齐拉西酮治疗双相情感障碍躁狂发作的临床效果显著,且安全性好,值得临床推广。
出处 《河南医学研究》 CAS 2016年第8期1462-1463,共2页 Henan Medical Research
  • 相关文献

参考文献6

二级参考文献44

  • 1粟幼嵩,陈俊,李则挚,王勇,黄佳,方贻儒,王祖承.碳酸锂联合阿立哌唑治疗双相障碍抑郁发作的疗效和安全性[J].上海交通大学学报(医学版),2011,31(11):1536-1539. 被引量:24
  • 2沈渔邨.精神病学[M].第4版.北京:人民卫生出版社,2005:351-352
  • 3Hirschfeld RM,Lewis L,Vomik LA. Perceptions and impact of bipolar disorder : how far have we really come?Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder[J]. J Clin Psychiatry, 2003,64 (3) : 167-174.
  • 4Grunze H,Kasper S,Goodwin G,et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders,part Q :treatment of mania [J]. World J Biol Psychiatry,2003,4(l ):5-13.
  • 5Ketter TA. Handbook of diagnosis and treatment of biporlar disorder[M]. Washington DC :American Psychiatric Pub,2010; 1-300.
  • 6Lopez-Jaramillo C, Lopera-V6squez J, Ospina-Duque J, et al. Lithium treatment effects on the neuropsychological functio- ning of patients with bipolar I disorder [J]. The Journal of Clinical Psychiatry ,2010,71 ( 8 ) : 1055-1060.
  • 7Lewis S, Geddes J, Goodwin G, et al. Lithium plus valproate combination therapy versus monotherapy for relapseprevention in bipolar I disorder (BALANCE) : a randomised open-label trial[ J]. Lancet,2010,375 (9712) :385-395.
  • 8Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, ran- domized, placebo-controlled, double-blind trial [ J ] The Jour- nal of Clinical Psychiatry,2010,71 (2) : 130-137.
  • 9Patkar A, Gilmer W, Pae C-u, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the a- cute depressive mixed state[J]. PloS one, 2012,7 ( 4 ) : 347- 357.
  • 10Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial [ J ]. The Journal of Clinical Psychia- try ,2011,72(10) :1413-1422.

共引文献75

同被引文献60

引证文献12

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部